Quiz|Articles|July 21, 2024
Targeted Pulse Quiz: July 21
Author(s)Morgan Bayer
Test your knowledge on the current pulse of oncology including FDA updates and breaking data with our Targeted Pulse Quiz.
Advertisement
Ready for the challenge? Let’s begin!
Which combination therapy showed superior progression-free survival compared with osimertinib for EGFR-mutated NSCLC?
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
NCCN Updates Breast Cancer Guidelines: Sacituzumab Govitecan for 1L TNBC
2
FDA Grants FTD to GPRC5D Bispecific LBL-034 for R/R Multiple Myeloma
3
Onvansertib Triplet Shows Dose-Dependent Frontline Benefit in RAS-Mutant Metastatic CRC
4
FDA Accepts BLA for Ivonescimab in Pretreated EGFR-Mutated NSCLC
5
















